Meera R. Hameed, MD

Meera R. Hameed, MD

Pathologist

Areas of Expertise

Conditions I Treat

  • Bone cancers and conditions
  • Soft tissue sarcomas

My Specialties

  • Surgical pathology
  • Molecular diagnostics
View all expertise
Dr. Hameed's Office Information
Languages: English
Request an Appointment
Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.
Back to top
English
Share

Get to Know Me

I am a pathologist with expertise in surgical pathology, molecular pathology, and clinical cytogenetics.

Read more

As a surgical pathologist, my particular expertise is bone and soft tissue (musculoskeletal) pathology. I work very closely with my clinical colleagues — including surgeons, radiologists, and medical oncologists. This collaboration has given me an in-depth understanding of clinical situations and has provided me the opportunity to participate as a team member with my clinical colleagues. I am an Invited Member of the International Skeletal Society — an organization of radiologists, pathologists, and surgeons who meet yearly to discuss rare and unusual presentations of the various bone and soft tissue neoplasms. I am also interested in teaching, and am a course co-director for orthopedic pathology at meetings of the U.S. and Canadian Academy of Pathology.

I am also a molecular pathologist with board certification in molecular genetic pathology, which allows me to keep abreast of latest developments in the fast-growing field of molecular oncology. As an invited member of the Molecular Oncology Committee of the College of American Pathologists, I serve as the committee member for the sarcoma sub-division and provide expertise on test development and appropriate molecular testing for sarcoma patients.

Clinical cytogenetics, in which I am also board certified, is a field where one studies chromosomal changes to interpret and provide pathological diagnostic correlations. My research involves exploring prognostic markers in bone and soft tissue neoplasms. For example, we have studied expression of markers with therapeutic significance, such as the EGFR family of tyrosine kinases in synovial sarcomas and osteosarcomas.

What I Do at MSK

I'm a pathologist, which is a doctor who uses a microscope to make a diagnosis from cell and tissue samples. I analyze these samples to learn the cause and effects of a health issue.

  • Chief, Surgical Pathology Service
Areas of Expertise

Conditions I Treat

  • Bone cancers and conditions
  • Soft tissue sarcomas

My Specialties

  • Surgical pathology
  • Molecular diagnostics
Education & Honors

Education

  • MD, Kilpaul Medical College Hospital (India)

Residencies

  • Kilpauk Medical College Hospital
  • Southern Railway Headquarters (India)
  • Hahnemann University Hospital

Fellowships

  • University of Connecticut Health Center
  • Hahnemann University Hospital
  • Memorial Sloan Kettering Cancer Center

Board Certifications

  • Anatomic and Clinical Pathology
  • Molecular Genetic Pathology

Awards and Honors

  • Castle Connolly: America’s Top Doctor (2025)
  • Castle Connolly: Top AAPI Doctor (2024)
  • Castle Connolly: Exceptional Women in Medicine (2024)
  • Castle Connolly: America’s Top Doctor (2024)
  • Top Doctors New York Metro Area, Castle Connolly (2023)
  • Exceptional Women in Medicine Award, Castle Connolly (2023)
  • Castle Connolly: America's Top Doctors (2023)

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Request an Opinion

Women talking
Request an Opinion
We can assess your case without an appointment. Click or call 212-639-6780— Monday through Friday, to (Eastern time)
Get a Consultation
Current Patients
Request an appointment by logging in to MSK MyChart or calling your Care Team. If you are not enrolled in MSK MyChart, ask your Care Team to send you an invitation. You can also go to MSK MyChart and select “Sign up now.”

Contact and Location

Dr. Hameed sees patients at one location.

Office Phone
Location
New York, NY
Memorial Sloan Kettering Cancer Center
1275 York Avenue New York NY 10065
Get Directions

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Leadership doctors

See all Molecular Diagnostics doctors

See all Surgical Pathology doctors

See all Pathology and Laboratory Medicine doctors

See all Diagnostic Molecular Pathology Service doctors

See all Bone and Soft Tissue Pathology doctors

Clinical Trials

Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Wang L, Zehir A, Sadowska J, Zhou N, Rosenblum M, Busam K, Agaram N, Travis W, Arcila M, Dogan S, Berger M, Cheng DT, Ladanyi M, Nafa K and Hameed M. Consistent copy number changes and recurrent PRKAR1A mutations distinguish melanotic schwannomas from melanomas: SNP array and next generation sequencing analysis. Genes Chromosomes Cancer. 2015; 54:463-471. PMC6446921.

Jour G, Wang L, Middha S, Zehir A, Chen W, Sadowska J, Healey J, Agaram NP, Choi L, Nafa K and Hameed M. The molecular landscape of extraskeletal osteosarcoma: a clinicopathological and molecular biomarker study. J. Pathol 2015; 2(1):9-20. PMC4858130.

Wang L, Zehir A, Nafa K, Zhou N, Berger MF, Casanova J, Sadowska J, Lu C, Allis DC, Gounder M, Chandhanayingyong C, Ladanyi M, Boland P and Hameed M. Genomic aberrations frequently alter chromatin regulatory genes in chordoma.  Genes, Chromosomes, Cancer 2016 Jul 55(7):591-600. PMC5031498.

Hanna MG, Reuter VE, Ardon O, Kim D, Sirintrapun SJ, Schüffler PJ, Busam KJ, Sauter JL, Brogi E, Tan LK, Xu B, Bale T, Agaram NP, Tang LH, Ellenson LH, Philip J, Corsale L, Stamelos E, Friedlander MA, Ntiamoah P, Labasin M, England C, Klimstra DS, Hameed M. Validation of a digital pathology system including remote review during the COVID-19 pandemic. Mod Pathol. 2020 Jun 22:1-13Mod Pathol. 2020 Jun 22:1-13. PMID: 32572154

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Meera R. Hameed discloses the following relationships and financial interests:

  • International Society of Bone and Soft Tissue Pathology
    Fiduciary Role / Position
  • United States & Canadian Academy of Pathology, USCAP
    Fiduciary Role / Position

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures

Related topics: